Kiniksa Pharmaceuticals International, plc (KNSA) · INSIDERData sourcesSEC Form 44h ago
House PTR4h ago
SEC 13F4h ago
Robinhood Chain4h ago
Public companyKiniksa Pharmaceuticals International, plc
KNSACIK 0001730430
Price$93.86
1 year+139.8%
Disclosed transactions60
Buys / sells0 / 19
Max Insider Score24
Connections with evidence8
KNSA · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 0 | PKPatel Sanj KDirector, CHAIRMAN & CEO | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | — 145.8K sh | Nov 4, 2026 |
| Nov 6, 2026 traded Nov 4, 2026 |
| 19 | PKPatel Sanj KDirector, CHAIRMAN & CEO | KNSAKiniksa Pharmaceuticals International, plc Open-market sale · 10b5-1 plan | SELL | $1.06M 11.3K sh | Nov 4, 2026 | Nov 6, 2026 traded Nov 4, 2026 | +2d | SEC Form 4 | |
| 19 | PKPatel Sanj KDirector, CHAIRMAN & CEO | KNSAKiniksa Pharmaceuticals International, plc Open-market sale · 10b5-1 plan | SELL | $2.85M 29.8K sh | Nov 4, 2026 | Nov 6, 2026 traded Nov 4, 2026 | +2d | SEC Form 4 | |
| 13 | PKPatel Sanj KDirector, CHAIRMAN & CEO | KNSAKiniksa Pharmaceuticals International, plc Open-market sale · 10b5-1 plan | SELL | $135K 1,460 sh | Nov 4, 2026 | Nov 6, 2026 traded Nov 4, 2026 | +2d | SEC Form 4 | |
| 19 | PKPatel Sanj KDirector, CHAIRMAN & CEO | KNSAKiniksa Pharmaceuticals International, plc Open-market sale · 10b5-1 plan | SELL | $2.59M 26.9K sh | Nov 4, 2026 | Nov 6, 2026 traded Nov 4, 2026 | +2d | SEC Form 4 | |
| 23 | PKPatel Sanj KDirector, CHAIRMAN & CEO | KNSAKiniksa Pharmaceuticals International, plc Open-market sale · 10b5-1 plan | SELL | $7.70M 81.7K sh | Nov 4, 2026 | Nov 6, 2026 traded Nov 4, 2026 | +2d | SEC Form 4 | |
| 12 | PKPatel Sanj KDirector, CHAIRMAN & CEO | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | $2.61M 145.8K sh | Nov 4, 2026 | Nov 6, 2026 traded Nov 4, 2026 | +2d | SEC Form 4 | |
| 0 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | — 3,760 sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC Form 4 | |
| 7 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | — 10.9K sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC Form 4 | |
| 4 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | — 9,412 sh | Nov 2, 2026 | Nov 3, 2026 traded Nov 2, 2026 | +1d | SEC Form 4 | |
| 20 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Open-market sale · 10b5-1 plan | SELL | $596K 6,282 sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC Form 4 | |
| 10 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | $234K 21.1K sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC Form 4 | |
| 24 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Open-market sale · 10b5-1 plan | SELL | $1.08M 11.6K sh | Nov 2, 2026 | Nov 3, 2026 traded Nov 2, 2026 | +1d | SEC Form 4 | |
| 17 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Open-market sale · 10b5-1 plan | SELL | $822K 8,932 sh | Nov 2, 2026 | Nov 3, 2026 traded Nov 2, 2026 | +1d | SEC Form 4 | |
| 23 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Open-market sale · 10b5-1 plan | SELL | $3.48M 37.8K sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC Form 4 | |
| 9 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | $286K 16.1K sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC Form 4 | |
| 4 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | — 12.3K sh | Nov 2, 2026 | Nov 3, 2026 traded Nov 2, 2026 | +1d | SEC Form 4 | |
| 0 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | — 6,263 sh | Nov 2, 2026 | Nov 3, 2026 traded Nov 2, 2026 | +1d | SEC Form 4 | |
| 10 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | $173K 16.1K sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC Form 4 | |
| 2 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | $197K 10.9K sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC Form 4 | |
| 20 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Open-market sale · 10b5-1 plan | SELL | $252K 2,575 sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC Form 4 | |
| 7 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | $170K 9,412 sh | Nov 2, 2026 | Nov 3, 2026 traded Nov 2, 2026 | +1d | SEC Form 4 | |
| 0 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | — 1,658 sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC Form 4 | |
| 0 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | — 16.1K sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC Form 4 | |
| 20 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Open-market sale · 10b5-1 plan | SELL | $792K 8,430 sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC Form 4 | |
| 0 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | $45K 3,760 sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC Form 4 | |
| 20 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Open-market sale · 10b5-1 plan | SELL | $353K 3,672 sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC Form 4 | |
| 0 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | $143K 6,263 sh | Nov 2, 2026 | Nov 3, 2026 traded Nov 2, 2026 | +1d | SEC Form 4 | |
| 0 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | $22K 1,658 sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC Form 4 | |
| 23 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Open-market sale · 10b5-1 plan | SELL | $1.40M 15.1K sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC Form 4 | |
| 13 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Open-market sale · 10b5-1 plan | SELL | $610K 6,681 sh | Nov 2, 2026 | Nov 3, 2026 traded Nov 2, 2026 | +1d | SEC Form 4 | |
| 10 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Open-market sale · 10b5-1 plan | SELL | $68K 722 sh | Nov 2, 2026 | Nov 3, 2026 traded Nov 2, 2026 | +1d | SEC Form 4 | |
| 0 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | — 16.1K sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC Form 4 | |
| 0 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | — 21.1K sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC Form 4 | |
| 13 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Open-market sale · 10b5-1 plan | SELL | $171K 1,760 sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC Form 4 | |
| 10 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | $268K 12.3K sh | Nov 2, 2026 | Nov 3, 2026 traded Nov 2, 2026 | +1d | SEC Form 4 | |
| 15 | MHMalkani Dhiraj HCHIEF STRATEGY OFFICER | KNSAKiniksa Pharmaceuticals International, plc Grant or award | A | — 2,119 sh | Jul 1, 2026 | Jul 6, 2026 traded Jul 1, 2026 | +5d | SEC Form 4 | |
| 15 | MHMalkani Dhiraj HCHIEF STRATEGY OFFICER | KNSAKiniksa Pharmaceuticals International, plc Grant or award | A | — 1,307 sh | Jul 1, 2026 | Jul 6, 2026 traded Jul 1, 2026 | +5d | SEC Form 4 | |
| 15 | MHMalkani Dhiraj HCHIEF STRATEGY OFFICER | KNSAKiniksa Pharmaceuticals International, plc Grant or award | A | — 82.6K sh | Jul 1, 2026 | Jul 6, 2026 traded Jul 1, 2026 | +5d | SEC Form 4 | |
| 15 | MHMalkani Dhiraj HCHIEF STRATEGY OFFICER | KNSAKiniksa Pharmaceuticals International, plc Grant or award | A | — 14.0K sh | Jul 1, 2026 | Jul 6, 2026 traded Jul 1, 2026 | +5d | SEC Form 4 | |
| 15 | MHMalkani Dhiraj HCHIEF STRATEGY OFFICER | KNSAKiniksa Pharmaceuticals International, plc Grant or award | A | — 2,188 sh | Jul 1, 2026 | Jul 6, 2026 traded Jul 1, 2026 | +5d | SEC Form 4 | |
| 15 | MHMalkani Dhiraj HCHIEF STRATEGY OFFICER | KNSAKiniksa Pharmaceuticals International, plc Grant or award | A | — 1,245 sh | Jul 1, 2026 | Jul 6, 2026 traded Jul 1, 2026 | +5d | SEC Form 4 | |
| 8 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Open-market sale · 10b5-1 plan | SELL | $80K 1,703 sh | Apr 9, 2026 | Apr 13, 2026 traded Apr 9, 2026 | +4d | SEC Form 4 | |
| 5 | RMRagosa MarkCHIEF FINANCIAL OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise | M | — 2,694 sh | Apr 7, 2026 | Apr 8, 2026 traded Apr 7, 2026 | +1d | SEC Form 4 | |
| 9 | TETessari EbenCHIEF STRATEGY OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise | M | — 2,726 sh | Apr 7, 2026 | Apr 8, 2026 traded Apr 7, 2026 | +1d | SEC Form 4 | |
| 12 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Open-market sale · 10b5-1 plan | SELL | $115K 2,367 sh | Apr 6, 2026 | Apr 8, 2026 traded Apr 6, 2026 | +2d | SEC Form 4 | |
| 12 | PFPaolini John F.CHIEF MEDICAL OFFICER | KNSAKiniksa Pharmaceuticals International, plc Tax withholding | F | $59K 1,208 sh | Apr 7, 2026 | Apr 8, 2026 traded Apr 7, 2026 | +1d | SEC Form 4 | |
| 9 | PFPaolini John F.CHIEF MEDICAL OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise | M | — 2,497 sh | Apr 7, 2026 | Apr 8, 2026 traded Apr 7, 2026 | +1d | SEC Form 4 | |
| 9 | PFPaolini John F.CHIEF MEDICAL OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise | M | — 2,497 sh | Apr 7, 2026 | Apr 8, 2026 traded Apr 7, 2026 | +1d | SEC Form 4 | |
| 0 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | — 2,477 sh | Apr 7, 2026 | Apr 8, 2026 traded Apr 7, 2026 | +1d | SEC Form 4 | |
| 0 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Tax withholding · 10b5-1 plan | F | $38K 774 sh | Apr 7, 2026 | Apr 8, 2026 traded Apr 7, 2026 | +1d | SEC Form 4 | |
| 3 | MRMoat RossCHIEF OPERATING OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | — 2,477 sh | Apr 7, 2026 | Apr 8, 2026 traded Apr 7, 2026 | +1d | SEC Form 4 | |
| 5 | TETessari EbenCHIEF STRATEGY OFFICER | KNSAKiniksa Pharmaceuticals International, plc Tax withholding | F | $41K 846 sh | Apr 7, 2026 | Apr 8, 2026 traded Apr 7, 2026 | +1d | SEC Form 4 | |
| 12 | RMRagosa MarkCHIEF FINANCIAL OFFICER | KNSAKiniksa Pharmaceuticals International, plc Tax withholding | F | $64K 1,303 sh | Apr 7, 2026 | Apr 8, 2026 traded Apr 7, 2026 | +1d | SEC Form 4 | |
| 9 | RMRagosa MarkCHIEF FINANCIAL OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise | M | — 2,694 sh | Apr 7, 2026 | Apr 8, 2026 traded Apr 7, 2026 | +1d | SEC Form 4 | |
| 5 | TETessari EbenCHIEF STRATEGY OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise | M | — 2,726 sh | Apr 7, 2026 | Apr 8, 2026 traded Apr 7, 2026 | +1d | SEC Form 4 | |
| 0 | RMRagosa MarkCHIEF FINANCIAL OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | — 8,374 sh | Feb 9, 2026 | Feb 11, 2026 traded Feb 9, 2026 | +2d | SEC Form 4 | |
| 6 | RMRagosa MarkCHIEF FINANCIAL OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | $109K 8,374 sh | Feb 9, 2026 | Feb 11, 2026 traded Feb 9, 2026 | +2d | SEC Form 4 | |
| 0 | RMRagosa MarkCHIEF FINANCIAL OFFICER | KNSAKiniksa Pharmaceuticals International, plc Option exercise · 10b5-1 plan | M | $42K 2,471 sh | Feb 9, 2026 | Feb 11, 2026 traded Feb 9, 2026 | +2d | SEC Form 4 | |
| 15 | RMRagosa MarkCHIEF FINANCIAL OFFICER | KNSAKiniksa Pharmaceuticals International, plc Open-market sale · 10b5-1 plan | SELL | $382K 8,731 sh | Feb 9, 2026 | Feb 11, 2026 traded Feb 9, 2026 | +2d | SEC Form 4 | |
CHIEF MEDICAL OFFICER · Apr 8, 2026
Moat RossCHIEF OPERATING OFFICER · Apr 8, 2026 Planned sales and 5% stakes
Form 144, 13D and 13G- RMRagosa MarkOfficer · sale around Nov 2, 2026 · 36.8K shares · 10b5-1 plan$3.39MForm 144 · filed Nov 2, 2026
- PFPaolini John F.Officer · sale around Oct 30, 2026 · 96.0K shares · 10b5-1 plan$8.93MForm 144 · filed Oct 30, 2026
- MRMegna Michael ROfficer · sale around Oct 30, 2026 · 47.5K shares · 10b5-1 plan$4.56MForm 144 · filed Oct 30, 2026
- MRMoat RossOfficer · sale around Oct 30, 2026 · 103.6K shares · 10b5-1 plan$9.75MForm 144 · filed Oct 30, 2026
- PKPatel Sanj KOfficer, Director · sale around Oct 30, 2026 · 553.8K shares · 10b5-1 plan$51.57MForm 144 · filed Oct 30, 2026